v3.25.2
Significant Collaborative Research and License Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Oct. 31, 2017
Jul. 31, 2016
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Jun. 30, 2022
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2016
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Research and development         $ 62,227   $ 48,655   $ 123,863 $ 105,147  
Total revenues         37,958   $ 3,500   57,753 $ 3,500  
Incyte Agreement [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Common stock shares purchased 1,421,523                    
Purchase price per share $ 24.62                    
Proceeds from issuance of common stock $ 35,000                    
Collaboration receivable         16,600       16,600    
Collaboration Loss         9,400            
Collaboration expense due to counterparty         4,300       4,300    
Incyte Agreement [Member] | Maximum [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Potential milestone payments to be made 220,000                    
Commercialization milestones and tiered royalties 230,000                    
Incyte Agreement [Member] | Non-Refundable Cash Payments [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Upfront milestone payable $ 117,000                    
Allergan License Agreement [Member] | Vitae Pharmaceuticals Inc [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Potential milestone payments to be made     $ 99,000   68,000       68,000    
Aggregate potential milestone payable     $ 70,000                
Milestone Expenses Paid         5,000       5,000    
Development and regulaotry milestones Expenses         31,000       31,000    
License expiration year     10 years                
Ucb License Agreement [Member] | U C B Biopharma [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Research and development                     $ 5,000
Milestone paid           $ 10,000          
Potential milestone payments to be made       $ 119,500 78,500       78,500    
Aggregate potential milestone payable       $ 250,000              
Development and regulaotry milestones Expenses         $ 41,000       $ 41,000    
License expiration year       10 years              
Milestone payment payable               $ 5,800      
Global and U.S. [Member] | Incyte Agreement [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Development costs associated with clinical trials   45.00%                  
Global and U.S. [Member] | Incyte Agreement [Member] | Incyte Corporation [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Development costs associated with clinical trials   55.00%                  
Ex-U.S. Countries [Member] | Incyte Agreement [Member]                      
Research And Development Arrangement Contract To Perform For Others [Line Items]                      
Development costs associated with clinical trials   100.00%